Abstract
Inhaled aclidinium (Eklira® Genuair® [EU]; Bretaris® Genuair® [EU]; Tudorza™ Pressair™ [US]) is a long-acting antimuscarinic agent. In the EU, it is indicated as maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD). Aclidinium provides improvements in lung function, dyspnoea and disease-specific health status in patients with COPD, and is generally well tolerated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.